Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix presents new data from bexobrutideg Ph 1a/1b clinical trial in patients with r/r CLL and updates in patients with WM at #ASH25
October 30, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
October 27, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
October 22, 2025 07:20 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
October 22, 2025 06:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for...
October 18, 2025 03:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607...
October 09, 2025 16:01 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479),...
September 17, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences
August 28, 2025 16:01 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
July 09, 2025 16:01 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and...